|
1
|
Sharifi M, Bay C, Mehdipour M and Sharifi
J; TORPEDO Investigators: Thrombus obliteration by rapid
percutaneous endovenous intervention in deep venous occlusion
(TORPEDO) trial: Midterm results. J Endovasc Ther. 19:273–280.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Meissner MH, Gloviczki P, Comerota AJ,
Dalsing MC, Eklof BG, Gillespie DL, Lohr JM, McLafferty RB, Murad
MH, Padberg F, et al Society for Vascular Surgery; American Venous
Forum: Early thrombus removal strategies for acute deep venous
thrombosis: Clinical practice guidelines of the Society for
Vascular Surgery and the American Venous Forum. J Vasc Surg.
55:1449–1462. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Santin BJ, Lohr JM, Panke TW, Neville PM,
Felinski MM, Kuhn BA, Recht MH and Muck PE: Venous duplex and
pathologic differences in thrombus characteristics between de novo
deep vein thrombi and endovenous heat-induced thrombi. J Vasc Surg
Venous Lymphat Disord. 3:184–189. 2015. View Article : Google Scholar
|
|
4
|
Sevuk U, Altindag R, Bahadir MV, Ay N,
Demirtas E and Ayaz F: Value of platelet indices in identifying
complete resolution of thrombus in deep venous thrombosis patients.
Indian J Hematol Blood Transfus. 31:71–76. 2015. View Article : Google Scholar
|
|
5
|
Comerota AJ and Paolini D: Treatment of
acute iliofemoral deep venous thrombosis: a strategy of thrombus
removal. Eur J Vasc Endovasc Surg. 33:351–362. 2007. View Article : Google Scholar
|
|
6
|
Vucić N, Magdić T, Krnić A, Vcev A and
Bozić D: Thrombus size is associated with etiology of deep venous
thrombosis - a cross-sectional study. Coll Antropol. 29:643–647.
2005.
|
|
7
|
Kölbel T, Alhadad A, Acosta S, Lindh M,
Ivancev K and Gottsäter A: Thrombus embolization into IVC filters
during catheter-directed thrombolysis for proximal deep venous
thrombosis. J Endovasc Ther. 15:605–613. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aziz F and Comerota AJ: Quantity of
residual thrombus after successful catheter-directed thrombolysis
for iliofemoral deep venous thrombosis correlates with recurrence.
Eur J Vasc Endovasc Surg. 44:210–213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dong DN, Wu XJ, Zhang SY, Zhong ZY and Jin
X: Clinical analysis of patients with lower extremity deep venous
thrombosis complicated with inferior vena cava thrombus. Zhonghua
Yi Xue Za Zhi. 93:1611–1614. 2013.In Chinese. PubMed/NCBI
|
|
10
|
Shi J, Zhi P, Chen J, Wu P and Tan S:
Genetic variations in the thrombin-activatable fibrinolysis
inhibitor gene and risk of cardiovascular disease: A systematic
review and meta-analysis. Thromb Res. 134:610–616. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bavbek N, Ceri M, Akdeniz D, Kargili A,
Duranay M, Erdemli K, Akcay A and Guz G: Higher thrombin
activatable fibrinolysis inhibitor levels are associated with
inflammation in attack-free familial Mediterranean fever patients.
Ren Fail. 36:743–747. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sherif EM, Elbarbary NS, Abd Al Aziz MM
and Mohamed SF: Plasma thrombin-activatable fibrinolysis inhibitor
levels in children and adolescents with type 1 diabetes mellitus:
possible relation to diabetic microvascular complications. Blood
Coagul Fibrinolysis. 25:451–457. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tsantes AE, Nikolopoulos GK, Bagos PG,
Rapti E, Mantzios G, Kapsimali V and Travlou A: Association between
the plasminogen activator inhibitor-1 4G/5G polymorphism and venous
thrombosis. A meta-analysis. Thromb Haemost. 97:907–913.
2007.PubMed/NCBI
|
|
14
|
Dubis J, Zuk N, Grendziak R, Zapotoczny N,
Pfanhauser M and Witkiewicz W: Activity of thrombin-activatable
fibrinolysis inhibitor in the plasma of patients with abdominal
aortic aneurysm. Blood Coagul Fibrinolysis. 25:226–231. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Naderi M, Dorgalaleh A, Alizadeh S,
Kashani Khatib Z, Tabibian S, Kazemi A, Dargahi H and Bamedi T:
Polymorphism of thrombin-activatable fibrinolysis inhibitor and
risk of intra-cranial haemorrhage in factor XIII deficiency.
Haemophilia. 20:e89–e92. 2014. View Article : Google Scholar
|
|
16
|
Plug T and Meijers JC: New clues regarding
the mysterious mechanism of activated thrombin-activatable
fibrinolysis inhibitor self-destruction. J Thromb Haemost.
13:1081–1083. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oztuzcu S, Ergun S, Ulaşlı M, Nacarkahya
G, Iğci YZ, Iğci M, Bayraktar R, Tamer A, Çakmak EA and Arslan A:
Evaluation of Factor V G1691A, prothrombin G20210A, Factor XIII
V34L, MTHFR A1298C, MTHFR C677T and PAI-1 4G/5G genotype
frequencies of patients subjected to cardiovascular disease (CVD)
panel in south-east region of Turkey. Mol Biol Rep. 41:3671–3676.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hilbers FS, Boekel NB, van den Broek AJ,
van Hien R, Cornelissen S, Aleman BM, van't Veer LJ, van Leeuwen FE
and Schmidt MK: Genetic variants in TGFbeta-1 and PAI-1 as possible
risk factors for cardiovascular disease after radiotherapy for
breast cancer. Radiother Oncol. 102:115–121. 2012. View Article : Google Scholar
|
|
19
|
Heineking B, Riebel T, Scheer I, Kulozik
A, Hoehn T and Bührer C: Intraventricular hemorrhage in a full-term
neonate associated with sinus venous thrombosis and homozygosity
for the plasminogen activator inhibitor-1 4G/4G polymorphism.
Pediatr Int. 45:93–96. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lichy C, Kloss M, Reismann P, Genius J,
Grau A and Reuner K: No evidence for plasminogen activator
inhibitor 1 4G/4G genotype as risk factor for cerebral venous
thrombosis. J Neurol. 254:1124–1125. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ringelstein M, Jung A, Berger K, Stoll M,
Madlener K, Klötzsch C, Schlachetzki F and Stolz E: Promotor
polymorphisms of plasminogen activator inhibitor-1 and other
thrombophilic genotypes in cerebral venous thrombosis: A
case-control study in adults. J Neurol. 259:2287–2292. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mutch NJ, Moore NR, Wang E and Booth NA:
Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. J
Thromb Haemost. 1:2000–2007. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhai K, Tang Y, Zhang Y, Li F, Wang Y, Cao
Z, Yu J, Kou J and Yu B: NMMHC IIA inhibition impedes tissue factor
expression and venous thrombosis via Akt/GSK3β-NF-κB signalling
pathways in the endothelium. Thromb Haemost. 114:173–185. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li YD, Ye BQ, Zheng SX, Wang JT, Wang JG,
Chen M, Liu JG, Pei XH, Wang LJ, Lin ZX, et al: NF-kappaB
transcription factor p50 critically regulates tissue factor in deep
vein thrombosis. J Biol Chem. 284:4473–4483. 2009. View Article : Google Scholar :
|
|
25
|
Hashikata T, Yamaoka-Tojo M, Namba S,
Kitasato L, Kameda R, Murakami M, Niwano H, Shimohama T, Tojo T and
Ako J: Rivaroxaban inhibits angiotensin II-induced activation in
cultured mouse cardiac fibroblasts through the modulation of NF-κB
pathway. Int Heart J. 56:544–550. 2015. View Article : Google Scholar
|
|
26
|
Wai-Hoe L, Wing-Seng L, Ismail Z and
Lay-Harn G: SDS-PAGE-based quantitative assay for screening of
kidney stone disease. Biol Proced Online. 11:145–160. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Samoš M, Bolek T, Ivanková J, Stančiaková
L, Kovář F, Galajda P, Kubisz P, Staško J and Mokáň M: Heparin
induced thrombocy-topenia presenting with deep venous thrombosis
and pulmonary embolism successfully treated with rivaroxaban:
Clinical case report and review of current experiences. J
Cardiovasc Pharmacol. 68:391–394. 2016. View Article : Google Scholar
|
|
28
|
Dirani M, Nasreddine W, Abdulla F and
Beydoun A: Seizure control and improvement of neurological
dysfunction in Lafora disease with perampanel. Epilepsy Behav Case
Rep. 2:164–166. 2014. View Article : Google Scholar
|
|
29
|
Massberg S, Gawaz M, Grüner S, Schulte V,
Konrad I, Zohlnhöfer D, Heinzmann U and Nieswandt B: A crucial role
of glycoprotein VI for platelet recruitment to the injured arterial
wall in vivo. J Exp Med. 197:41–49. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nuutila J, Hohenthal U, Laitinen I,
Kotilainen P, Rajamäki A, Nikoskelainen J and Lilius EM:
Simultaneous quantitative analysis of FcgammaRI (CD64) expression
on neutrophils and monocytes: A new, improved way to detect
infections. J Immunol Methods. 328:189–200. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chuchalin AG, Tseimakh IY, Momot AR,
Mamaev AN, Karbyshev IA and Strozenko LA: Thrombogenic risk factors
in patients with exacerbation of chronic obstructive pulmonary
disease. Klin Med (Mosk). 93:18–23. 2015.In Russian.
|
|
32
|
Cheung YW, Middeldorp S, Prins MH, Pap AF,
Lensing AW, Ten Cate-Hoek AJ, Villalta S, Milan M, Beyer-Westendorf
J, Verhamme P, et al Einstein PTS Investigators Group:
Post-thrombotic syndrome in patients treated with rivaroxaban or
enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A
post-hoc analysis. Thromb Haemost. 116:733–738. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Deitelzweig S, Laliberté F, Crivera C,
Germain G, Bookhart BK, Olson WH, Schein J and Lefebvre P:
Hospitalizations and other health care resource utilization among
patients with deep vein thrombosis treated with rivaroxaban versus
low-molecular-weight heparin and warfarin in the outpatient
setting. Clin Ther. 38:1803–1816.e1803. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wan H, Yang Y, Zhu J, Wu S, Zhou Z, Huang
B, Wang J, Shao X and Zhang H: An in-vitro evaluation of direct
thrombin inhibitor and factor Xa inhibitor on tissue factor-induced
thrombin generation and platelet aggregation: A comparison of
dabigatran and rivaroxaban. Blood Coagul Fibrinolysis. 27:882–885.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shlebak A: Antiphospholipid syndrome
presenting as cerebral venous sinus thrombosis: A case series and a
review. J Clin Pathol. 69:337–343. 2016. View Article : Google Scholar
|
|
36
|
Blum A and Shamburek R: The pleiotropic
effects of statins on endothelial function, vascular inflammation,
immunomodulation and thrombogenesis. Atherosclerosis. 203:325–330.
2009. View Article : Google Scholar
|
|
37
|
Lee KW, Blann AD and Lip GY: Plasma
markers of endothelial damage/dysfunction, inflammation and
thrombogenesis in relation to TIMI risk stratification in acute
coronary syndromes. Thromb Haemost. 94:1077–1083. 2005.PubMed/NCBI
|
|
38
|
Terry CM, He Y and Cheung AK: Rivaroxaban
improves patency and decreases inflammation in a mouse model of
catheter thrombosis. Thromb Res. 144:106–112. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shah PK: Thrombogenic risk factors for
atherothrombosis. Rev Cardiovasc Med. 7:10–16. 2006.PubMed/NCBI
|
|
40
|
Chu NF, Spiegelman D, Hotamisligil GS,
Rifai N, Stampfer M and Rimm EB: Plasma insulin, leptin, and
soluble TNF receptors levels in relation to obesity-related
atherogenic and thrombogenic cardiovascular disease risk factors
among men. Atherosclerosis. 157:495–503. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pacheco YM, Bermúdez B, López S, Abia R,
Villar J and Muriana FJ: Ratio of oleic to palmitic acid is a
dietary determinant of thrombogenic and fibrinolytic factors during
the postprandial state in men. Am J Clin Nutr. 84:342–349.
2006.PubMed/NCBI
|
|
42
|
Hartweg J, Farmer AJ, Holman RR and Neil
HA: Meta-analysis of the effects of n-3 polyunsaturated fatty acids
on haematological and thrombogenic factors in type 2 diabetes.
Diabetologia. 50:250–258. 2007. View Article : Google Scholar
|
|
43
|
Juhan-Vague I, Alessi MC and Vague P:
Thrombogenic and fibrinolytic factors and cardiovascular risk in
non-insulin-dependent diabetes mellitus. Ann Med. 28:371–380. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dewyer NA, Sood V, Lynch EM, Luke CE,
Upchurch GR Jr, Wakefield TW, Kunkel S and Henke PK: Plasmin
inhibition increases MMP-9 activity and decreases vein wall
stiffness during venous thrombosis resolution. J Surg Res.
142:357–363. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nosaka M, Ishida Y, Kimura A and Kondo T:
Immunohistochemical detection of MMP-2 and MMP-9 in a
stasis-induced deep vein thrombosis model and its application to
thrombus age estimation. Int J Legal Med. 124:439–444. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Malaponte G, Polesel J, Candido S,
Sambataro D, Bevelacqua V, Anzaldi M, Vella N, Fiore V, Militello
L, Mazzarino MC, et al: IL-6-174 G>C and MMP-9-1562 C>T
polymorphisms are associated with increased risk of deep vein
thrombosis in cancer patients. Cytokine. 62:64–69. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bhaskar S, Sudhakaran PR and Helen A:
Quercetin attenuates atherosclerotic inflammation and adhesion
molecule expression by modulating TLR-NF-κB signaling pathway. Cell
Immunol. 310:131–140. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
García-Trapero J, Carceller F, Dujovny M
and Cuevas P: Perivascular delivery of neomycin inhibits the
activation of NF-kappaB and MAPK pathways, and prevents neointimal
hyperplasia and stenosis after arterial injury. Neurol Res.
26:816–824. 2004. View Article : Google Scholar
|
|
49
|
Gao MY, Chen L, Yang L, Yu X, Kou JP and
Yu BY: Berberine inhibits LPS-induced TF procoagulant activity and
expression through NF-κB/p65 Akt and MAPK pathway in THP-1 cells.
Pharmacol Rep. 66:480–484. 2014. View Article : Google Scholar : PubMed/NCBI
|
